Clarity Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
|Primary activities||Clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology.|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||National Innovation Centre 4 Cornwallis Street Eveleigh Sydney NSW 2015 Australia|
|Phone / Fax||61 2 9209 4037 /|
|Share registry||LINK MARKET SERVICES LIMITED|
Clarity Pharmaceuticals does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Clarity Pharmaceuticals.
|Dr. Alan John Taylor Ph.D.||Exec. Chairman||818.33k|
|Dr. Colin David Biggin Ph.D.||MD, CEO & Exec. Director||427.37k|
|Mr. Robert Vickery||CFO & Company Sec.||168.29k|
|Dr. Matthew Harris M.B.A., BSc., Ph.D.||Chief Scientific Officer||195.43k|
|Dr. Michael D. Ironside||Director of Operations|
|Dr. Ellen van Dam Ph.D.||Head of R&D|
|Mr. Shaemus Gleason||Exec. VP of US Operations|
|Dr. Robert M. Miller Ph.D.||Consultant Chief Medical Officer||68|
|Mr. William Cheadle||Financial Controller|
|Mr. Anthony Romagnino MBA||Bus. Devel. Mang.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Clarity Pharmaceuticals is 322.73M and its enterprise value is 220.99M. The enterprise value to revenue ratio of CU6 is 69.14.
Companies similar to Clarity Pharmaceuticals (CU6)
Clarity Pharmaceuticals (ASX:CU6) Frequently Asked Questions
1. What is Clarity Pharmaceuticals's Stock Symbol?
Clarity Pharmaceuticals trades on ASX under the ticker symbol "CU6".
2. What is Clarity Pharmaceuticals's stock price today?
One share of CU6 stock can currently be purchased for approximately $1.26.
3. How can I contact Clarity Pharmaceuticals?
Clarity Pharmaceuticals's mailing address is National Innovation Centre 4 Cornwallis Street Eveleigh Sydney NSW 2015 Australia. The company can be reached via phone at 61 2 9209 4037.
4. What is Clarity Pharmaceuticals's official website?
The official website of Clarity Pharmaceuticals is http://www.claritypharmaceuticals.com.
5. Which share registry manages Clarity Pharmaceuticals's stock?
Clarity Pharmaceuticals's stock is managed by LINK MARKET SERVICES LIMITED.